This work develops the nonparametric efficiency theory and derive the efficient influence function for the cumulative incidence of an event under a DTR in the presence of a competing risk and right-censoring and proposes a sequentially doubly robust estimator that accommodates flexible machine learning for nuisance estimation while retaining root-n consistency and asymptotic normality.
Abstract
Many observational studies evaluate the risks and benefits of time-varying interventions. In these longitudinal settings, the primary outcome of interest is often a clinical event that is precluded by mortality, which acts as a competing risk. Evaluating dynamic treatment regimes (DTRs) is complicated by time-varying confounding, right-censoring, and progressive sample size reduction over time, for which traditional methods such as the g-formula or inverse probability weighting may be misspecified or highly unstable. In this work, we develop the nonparametric efficiency theory and derive the efficient influence function for the cumulative incidence of an event under a DTR in the presence of a competing risk and right-censoring. Building on this result, we propose a sequentially doubly robust estimator that accommodates flexible machine learning for nuisance estimation while retaining root-n consistency and asymptotic normality. We illustrate the utility of our framework by estimating long-term cumulative incidence of clinical fractures under different bisphosphonate"drug holiday"regimes for osteoporosis.
This work proposes a novel data-driven, adaptive procedure that identifies the optimal restriction time from a continuous range by maximizing a criterion balancing effect size and estimation precision, and provides a rigorous theoretical foundation that accounts for the additional variability introduced by adaptive sel...
Jing-Hao Sun, D. Schaubel, E. T. Tchetgen Tchetgen· Biometrika· 0 citations
Dynamic risk assessment is an important tool for healthcare providers to inform treatment selection and optimize patient outcomes. Frequent evaluation of clinical status provides invaluable information on adverse event risk and/or treatment urgency, based on the changes in predictive biomarkers. Landmark analysis is a...
Yuan Zhang, D. Schaubel· Lifetime Data Analysis· 0 citations
Time-to-event outcomes are central in oncology and rare diseases, where treatment effects are often summarized by differences in survival curves or Restricted Mean Survival Time (RMST). In real-world data, estimating these causal effects relies on the absence of unobserved confounding, an assumption that is rarely sati...
Jean-Baptiste Baitairian, Bernard Sebastien, R. Jreich et al.· 0 citations
Randomized controlled trials provide internally valid estimates of treatment effects, but their results may not directly apply to broader target populations due to differences in baseline covariate distributions, adherence to treatment or variations in outcome mechanisms. Under standard transport and time-to-event iden...
Axel Martin, Iván Díaz, Michele Santacatterina· 0 citations
A direct ranking approach for conditional RMST treatment benefit in randomized trials with right-censored outcomes is proposed that combines orthogonal survival learning with pairwise ranking and may be particularly useful in precision medicine settings where treatment prioritization and patient selection are the prima...
Ling-Li Yang, Bing-Xia Wang, Tian-Long Chen et al.· 0 citations
Clinical trials and observational studies frequently encounter survival data with right censoring and high-dimensional confounders. This article proposes several estimators for assessing the average causal effect of a binary treatment on survival outcomes in the presence of confounders. These include doubly weighted es...
Chien-Lin Su· Statistical Methods in Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.